What 340B rebates could mean for hospital cash, staffing, per CEOs

Becker’s Hospital Review – Monday, September 28, 2026
By Kelly Gooch

The 340B Drug Pricing Program remains among the financial and policy issues hospital CEOs are watching closely, amid legal challenges and potential changes to how hospitals receive drug discounts.

In Sept. 23 comments on the SECURE 340B Act, the American Hospital Association asked Congress to permanently bar rebate models, arguing they would create cash flow and administrative challenges for hospitals.

Click here to read the entire article.